Health Condition 1: D631- Anemia in chronic kidney disease
Conditions
Interventions
Intervention1: Hypoxia Inducible Factor- Prolyl Hydroxylase Inhibitors: Oral drug that treats anaemia in Chronic Kidney Disease by mimicking exposure to hypoxia, stimulating endogenous erythropoietin
Sponsors
Gunn Goel
Eligibility
Inclusion criteria
Inclusion criteria: Patients with CKD stage 3, 4,5 (estimated Glomerular Filtration Rate below 60) with stable kidney function in past 3 months assessed by eGFR calculation with anemia (Hb less than 10 g per dL) who have given the consent to participate in the study shall be included in the study
Exclusion criteria
Exclusion criteria: 1.Patients already on Desidustat or EPO for treatment of anaemia prior to screening 2.Patients with a history of or active bleeding 3.Post kidney allograft transplantation 4.Pregnant or expectants 5.Patients on oral or parenteral Iron therapy 6.Patients with vitamin B12, Folate deficiency 7.Patients with underlying malignancy 8.Other causes of anaemia like Hemoglobinopathies, Autoimmune haemolytic anaemia, Hypersplenism, Bone marrow disorders etc 9.Patients with HIV 10.Patients with Cirrhosis 11.ADPKD patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.To detect change in reticulocyte indices from baseline after a short-term treatment with Desidustat and Standard EPO therapy. 2.To confirm role of Desidustat in mobilising iron stores.Timepoint: Monthly basis for 2 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To study differential impact of iron status on efficacy of Desidustat versus EPO therapy.Timepoint: Monthly basis for 2 months | — |
Countries
India
Contacts
Public ContactDr Saurabh Nayak
All India Institute of Medical Sciences Bathinda
Outcome results
None listed